tbuckley/cabot-search huggingface dataset:
Resident Forum
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Spironolactone Use With Risk of Cancer
Authors: Kanthi Bommareddy, Hassan Hamade, Maria A. Lopez-Olivo, Mackenzie Wehner, Traci Tosh, John S. Barbieri
Journal: JAMA Dermatology (2022)

While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism. However, spironolactone carries an official warning from the US Food and Drug Administration regarding potential for tumorigenicity.To determine the pooled occurrence of cancers, in particular breast and prostate cancers, among those who were ever treated with spironolactone.PubMed, Cochrane Library, Embase, and Web of Science were searched from inception through June 11, 2021. The search was restricted to studies in the English language.Included studies reported the occurrence of cancers in men and women 18 years and older who were exposed to spironolactone.Two independent reviewers (K.B. and H.H.) selected studies, extracted data, and appraised the risk of bias using the Newcastle-Ottawa Scale. Studies were synthesized using random effects meta-analysis.Cancer occurrence, with a focus on breast and prostate cancers.Seven studies met eligibility criteria, with sample sizes ranging from 18 035 to 2.3 million and a total population of 4 528 332 individuals (mean age, 62.6-72.0 years; in the studies without stratification by sex, women accounted for 17.2%-54.4%). All studies were considered to be of low risk of bias. No statistically significant association was observed between spironolactone use and risk of breast cancer (risk ratio [RR], 1.04; 95% CI, 0.86-1.22; certainty of evidence very low). There was an association between spironolactone use and decreased risk of prostate cancer (RR, 0.79; 95% CI, 0.68-0.90; certainty of evidence very low). There was no statistically significant association between spironolactone use and risk of ovarian cancer (RR, 1.52; 95% CI, 0.84-2.20; certainty of evidence very low), bladder cancer (RR, 0.89; 95% CI, 0.71-1.07; certainty of evidence very low), kidney cancer (RR, 0.96; 95% CI, 0.85-1.07; certainty of evidence low), gastric cancer (RR, 1.02; 95% CI, 0.80-1.24; certainty of evidence low), or esophageal cancer (RR, 1.09; 95% CI, 0.91-1.27; certainty of evidence low).In this systematic review and meta-analysis, spironolactone use was not associated with a substantial increased risk of cancer and was associated with a decreased risk of prostate cancer. However, the certainty of the evidence was low and future studies are needed, including among diverse populations such as younger individuals and those with acne or hirsutism.
Suppression of premature transcription termination leads to reduced mRNA isoform diversity and neurodegeneration
Authors: Geneva R. LaForce, Jordan S. Farr, Jingyi Liu, Cydni Akesson, Evren Gumus, Otis Pinkard, Helen C. Miranda, Katherine Johnson, Thomas J. Sweet, Ping Ji, Ai Lin, Jeff Coller, Polyxeni Philippidou, Eric J. Wagner, Ashleigh E. Schaffer
Journal: Neuron (2022)
Topical use of hyperoxygenated fatty acids decreases surgical site infection in patients following laparoscopic cholecystectomy. A randomized controlled trial
Authors: Marta Bellón López de Antón Bueno, Ana Murcia López, Antonio Galiana Cabrera, José Alberto García Gómez, Alicia Calero Amaro, Carlos Díaz Lara, Antonio Arroyo Sebastián, Javier Lacueva F. Gómez, Laura Armañanzas Ruiz
Journal: International Journal of Surgery (2022)
Thoracic Anaesthesia
Authors: Lucien E. Morris
Journal: JAMA (1964)

The editor-author of this 700-page book is to be congratulated for melding the efforts of an illustrious group of contributors into pleasing continuity. The reader is presumed to be already well versed in the knowledge and techniques of anesthesia for surgical intervention in other areas of the body. Consequently, there is no discussion of ordinary complications of anesthesia, nor is there space devoted to the pharmacology of various anesthetic agents or the ordinary equipment for administering gases and vapors. Instead, emphasis rests upon the medical and surgical problems with which a thoracic anesthetist must be conversant. The text begins by discussing the central problem of thoracic anesthesia, namely, the presence of pneumothorax and the necessary considerations in the management of this throughout the surgical procedure and subsequently. Chapters on the preoperative assessment of respiratory function and circulatory function are followed by equally well-written ones on the physiology of respiration and
Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus
Authors: Yann L. C. Becker, Jean‐Philippe Gagné, Anne‐Sophie Julien, Tania Lévesque, Isabelle Allaeys, Nadine Gougeard, Vicente Rubio, François‐Michel Boisvert, Dominique Jean, Eric Wagner, Guy G. Poirier, Paul R. Fortin, Éric Boilard
Journal: Arthritis & Rheumatology (2022)

Mitochondria are organelles that exhibit several bacterial features, such as a double-stranded genome with hypomethylated CpG islands, formylated proteins, and cardiolipin-containing membranes. In systemic lupus erythematosus (SLE), mitochondria and their inner components are released into the extracellular space, potentially eliciting a proinflammatory response from the immune system. While cardiolipin and mitochondrial DNA and RNA are confirmed targets of autoantibodies, other antigenic mitochondrial proteins in SLE remain to be identified. The present study was undertaken to characterize the protein repertoire recognized by antimitochondrial antibodies (AMAs) in patients with SLE. Using shotgun proteomic profiling, we identified 1,345 proteins, 431 of which were associated with the mitochondrial proteome. Immunoreactivities to several of these candidate proteins were assessed in serum samples from a local cohort (n = 30 healthy donors and 87 patients with SLE) using enzyme-linked immunosorbent assay, and further analyzed for associations with demographic and disease characteristics. We determined that IgG antibodies to the complement component C1q binding protein were significantly elevated in the patients with SLE (P = 0.049) and were also associated with lupus anticoagulant positivity (P = 0.049). Elevated levels of IgG antibodies against mitochondrial protein mitofusin 1 (MFN-1) were promising predictors of SLE diagnosis in our cohort (adjusted odds ratio 2.99 [95% confidence interval 1.39-6.43], P = 0.0044). Moreover, increased levels of anti-MFN-1 were associated with the presence of antiphospholipids (P = 0.011) and anti-double-stranded DNA (P = 0.0005). In this study, we characterized the mitochondrial repertoire targeted by AMAs in the setting of SLE. Our results indicate that autoantibodies can recognize secreted and/or surface proteins of mitochondrial origin. Profiling of the AMA repertoire in large prospective cohorts may improve our knowledge of mitochondrial biomarkers and their usefulness for patient stratification.
Prevalence of atrial thrombi in patients undergoing electrical cardioversion — results from the ACUTE registry
Authors: M. Thamilarasan, R.A. Grimm, M.J. Garcia, S.E. Vaughn, D.A. Agler, A. Morehead, J.A. Odabashian, L.A. Cardon, S.C. Enar, A.L. Klein
Journal: Journal of the American College of Cardiology (1998)
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
Authors: Laura Boekel, Femke Hooijberg, Yaëlle R Besten, Erik H Vogelzang, Maurice Steenhuis, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Willem F Lems, Wouter H Bos, Carla A Wijbrandts, Martijn Gerritsen, Charlotte Krieckaert, Alexandre E Voskuyl, Irene E van der Horst-Bruinsma, Sander W Tas, Maarten Boers, Theo Rispens, Michael T Nurmohamed, Gertjan Wolbink
Journal: The Lancet Rheumatology (2022)
Khirurgiia, Moscow
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting memory T cell metabolism to improve immunity
Authors: Mauro Corrado, Erika L. Pearce
Journal: Journal of Clinical Investigation (2022)

Vaccination affords protection from disease by activating pathogen-specific immune cells and facilitating the development of persistent immunologic memory toward the vaccine-specific pathogen. Current vaccine regimens are often based on the efficiency of the acute immune response, and not necessarily on the generation of memory cells, in part because the mechanisms underlying the development of efficient immune memory remain incompletely understood. This Review describes recent advances in defining memory T cell metabolism and how metabolism of these cells might be altered in patients affected by mitochondrial diseases or metabolic syndrome, who show higher susceptibility to recurrent infections and higher rates of vaccine failure. It discusses how this new understanding could add to the way we think about immunologic memory, vaccine development, and cancer immunotherapy.
Exhuming similarity
Authors: Dedre Gentner
Journal: Behavioral and Brain Sciences (2001)

Tenenbaum and Griffiths' paper attempts to subsume theories of similarity – including spatial models, featural models, and structure-mapping models – into a framework based on Bayesian generalization. But in so doing it misses significant phenomena of comparison. It would be more fruitful to examine how comparison processes suggest hypotheses than to try to derive similarity from Bayesian reasoning. [Shepard; Tenenbaum &amp; Griffiths]
Family Practice
Authors: William R. Willard
Journal: JAMA (1966)

The Ad Hoc Committee on Preparation for Family Practice was appointed by the Council on Medical Education of the American Medical Association in September 1964. It is composed of representatives from the Council on Medical Education, the Association of American Medical Colleges, the Academy of General Practice, and the Section on General Practice of the AMA. The Committee was given the following charge: To review present AMA policy regarding the future of family or general practice and to determine whether the goals of such a policy are being achieved. To recommend the educational approach by which present goals may be achieved if they are not being achieved now. To define and recommend the policies by which these goals may be achieved. Previous actions of the AMA's policy-making body, the House of Delegates, have affirmed a conviction of the House—that family practice is important for optimum health care.
The Psychiatric Study of Problem Children.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association Between Homelessness and Group A Streptococcus Skin and Soft Tissue Infections Among Hospitalized Dermatology Consult Patients
Authors: Adam Zakaria, Katrina Abuabara, John Szumowski, Penelope Kim-Lim, Lindy P. Fox, Erin H. Amerson, Aileen Y. Chang
Journal: JAMA Dermatology (2022)

Boas C. L. van der Putten, PhD; Bart J. M. Vlaminckx, MD, PhD; Brechje de Gier, PhD; Wieke Freudenburg-de Graaf, MD, PhD; Nina M. van Sorge, PhD
Estimated Population Access to Acute Stroke and Telestroke Centers in the US, 2019
Authors: Kori S. Zachrison, Rebecca E. Cash, Opeolu Adeoye, Krislyn M. Boggs, Lee H. Schwamm, Ateev Mehrotra, Carlos A. Camargo
Journal: JAMA Network Open (2022)

Highlights From the International Stroke Conference 2022—Thrombectomy and Alteplase, Access to Stroke Centers, and Warfarin vs Direct Oral Anticoagulants
AN ENCOURAGING SIGN.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The results of cardiac surgery during the COVID-19 pandemic compared with previous years: a propensity weighted study of outcomes at six months
Authors: Emily Day, Francesca Fiorentino, Mohamed Abdelkhalek, Hassiba Smail, Ulrich A Stock, Sunil Bhudia, Fabio De Robertis, Toufan Bahrami, Shahzad Raja, Jullien Gaer
Journal: Journal of the Royal Society of Medicine (2022)

Objectives In addition to excess mortality due to COVID-19, the pandemic has been characterised by excess mortality due to non-COVID diagnoses and consistent reports of patients delaying seeking medical treatment. This study seeks to compare the outcomes of cardiac surgery during and before the COVID-19 pandemic. Design Our institutional database was interrogated retrospectively to identify all patients undergoing one of three index procedures during the first six months of the pandemic and the corresponding epochs of the previous five years. Setting A regional cardiothoracic centre. Participants All patients undergoing surgery during weeks #13-37, 2015-2020. Main outcome measures Propensity score weighted analysis was employed to compare the incidence of major complications (stroke, renal failure, re-ventilation), 30-day mortality, six month survival and length of hospital stay between the two groups. Results There was no difference in 30-day mortality (HR = 0.76 [95% CI 0.27-2.20], p = 0.6211), 6-month survival (HR = 0.94 [95% CI 0.44-2.01], p = 0.8809) and duration of stay (SHR = 1.00 (95% CI 0.90-1.12), p = 0.959) between the two eras. There were no differences in the incidence of major complications (weighted chi-square test: renal failure: p = 0.923, stroke: p = 0.991, new respiratory failure: p = 0.856). Conclusions Cardiac surgery is as safe now as in the previous five years. Concerns over the transmission of COVID-19 in hospital are understandable but patients should be encouraged not to delay seeking medical attention. All involved in healthcare and the wider public should be reassured by these findings.
Association of Oncology Care Model Participation With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes—Reply
Authors: Nancy L. Keating, Andrea Hassol
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Authors: Yongkun Sun, Wen Zhang, Xinyu Bi, Zhengqiang Yang, Yu Tang, Liming Jiang, Feng Bi, Minshan Chen, Shuqun Cheng, Yihebali Chi, Yue Han, Jing Huang, Zhen Huang, Yuan Ji, Liqun Jia, Zhichao Jiang, Jing Jin, Zhengyu Jin, Xiao Li, Zhiyu Li, Jun Liang, Lianxin Liu, Yunpeng Liu, Yinying Lu, Shichun Lu, Qinghua Meng, Zuoxing Niu, Hongming Pan, Shukui Qin, Wang Qu, Guoliang Shao, Feng Shen, Tianqiang Song, Yan Song, Kaishan Tao, Aiping Tian, Jianhua Wang, Wenling Wang, Zhe Wang, Liqun Wu, Feng Xia, Baocai Xing, Jianming Xu, Huadan Xue, Dong Yan, Lin Yang, Jianming Ying, Jingping Yun, Zhaochong Zeng, Xuewen Zhang, Yanqiao Zhang, Yefan Zhang, Jianjun Zhao, Jianguo Zhou, Xu Zhu, Yinghua Zou, Jiahong Dong, Jia Fan, Wan Yee Lau, Yan Sun, Jinming Yu, Hong Zhao, Aiping Zhou, Jianqiang Cai
Journal: Liver Cancer (2022)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. &lt;b&gt;&lt;i&gt;Summary:&lt;/i&gt;&lt;/b&gt; For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. &lt;b&gt;&lt;i&gt;Key Messages:&lt;/i&gt;&lt;/b&gt; Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
Marriages
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again?
Authors: Roy H. Perlis, Maurizio Fava
Journal: JAMA Psychiatry (2022)

This Viewpoint revisits the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study design 20 years after its initiation and assesses it in light of current strategies to treat major depression.